Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
19.74
+0.81 (+4.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Akero Therapeutics Inc
< Previous
1
2
Next >
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
March 20, 2024
From
Abraham, Fruchter & Twersky, LLP
Via
GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 08, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
June 09, 2023
Via
Investor Brand Network
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
February 29, 2024
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
November 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 08, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
October 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
October 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
October 09, 2023
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
October 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
August 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
August 28, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
June 23, 2023
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses
From
Akero Therapeutics
Via
GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
June 09, 2023
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration.
Via
MarketBeat
Exposures
Product Safety
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
June 05, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
June 01, 2023
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 16, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
March 29, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.